A Phase I Study of LX22001 for Injection in Healthy Subjects
Recruiting now · Phase 1
Conditions studied: Healthy
In brief
Study to evaluate the safety and tolerability, pharmacokinetics/pharmacodynamics (PK/PD) parameters of an escalating, single dose/repeat doses of LX22001 for injection in healthy subjects.
Key facts
- Study ID
- NCT06561542
- Run by
- Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
- People needed
- 70
- Starts
- 2024-08-05
- Expected to finish
- 2025-11-21
- Last updated by the study team
- 2024-08-20
Who can join
Age: 18 and older, up to 45. Sex: any. Healthy volunteers: accepted.
Where it is running
- Peking Union Medical College Hospital, Chinese Academy of Medical Sciences — Beijing, Beijing Municipality, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.